null

Biosimilar Antibodies

Biosimilar Antibodies

Cost effective alternative to therapeutic antibodies!

Figure 1: ELISA plate precoated with 2 µg/ml Human CD47. Anti-CD47 (Magrolimab) biosimilar binds to Human CD47 and can be detected in a range of 0.061-1.606 ng/ml using a mFc-His tagged protein

What are Biosimilar Antibodies?

  • A biosimilar antibody is a copy of a therapeutic antibody, with highly similar quality and efficacy, that has been approved for medical use.
  • A therapeutic antibody is an antibody that is designed to recognise specific proteins on certain cells to iniate an immune response. Therapeutic antibodies are used to treat cancer, arthritis, Alzheimer's and other diseases.
  • Research-grade biosimilar antibodies offer a more readily available and cost effective alternative to the original therapeutic antibody and can serve as a reference antibody in the development of new biologics.

Popular Biosimlar Antibodies

Product Thumbnail
BAFF Biosimilar Antibody
Therapuetic Antibody Belimumab
Reactivity Human
Application ELISA
Product Thumbnail
4-1BB Biosimilar Antibody
Therapuetic Antibody Utomilumab
Reactivity Human
Application ELISA
Product Thumbnail
CD123 Biosimilar Antibody
Therapuetic Antibody Talacotuzumab
Reactivity Human
Application ELISA, Flow Cytometry
Product Thumbnail
CD38 Biosimilar Antibody
Therapuetic Antibody Daratumumab
Reactivity Human
Application ELISA, Flow Cytometry
Product Thumbnail
CTLA4 Biosimilar Antibody
Therapuetic Antibody Ipilimumab
Reactivity Human
Application ELISA
Product Thumbnail
IL6R Biosimilar Antibody
Therapuetic Antibody Tocilizumab
Reactivity Human
Application ELISA, Flow Cytometry
Product Thumbnail
Mesothelin Biosimilar Antibody
Therapuetic Antibody Amatuximab
Reactivity Human
Application ELISA
Product Thumbnail
PD-1 Biosimilar Antibody
Therapuetic Antibody Pembrolizumab
Reactivity Human
Application ELISA, Flow Cytometry
Product Thumbnail
PDL1 Biosimilar Antibody
Therapuetic Antibody Atezolizumab
Reactivity Human
Application ELISA, Flow Cytometry
Product Thumbnail
IL6 Biosimilar Antibody
Therapuetic Antibody Siltuximab
Reactivity Human
Application ELISA, Flow Cytometry

Looking for a particular biosimilar? Use our LiveChat to get in touch and one of our specialists will be happy to help!

Biosimilar Benefits

  • Premium | Research grade (RUO) biosimilar antibodies
  • Purified | Purified from cell supernatant by affinity chromatography
  • Validated | Validated for target binding verification and off target effects by ELISA and flow cytometry to ensure quality and specificity
  • Specific | Demonstrated to be low or non-immunogenic
  • Cost | Cost effective alternative to therapeutic antibodies

Figure 2: HEK293 cells transfected with (A) human CD47 or (B) control protein. Cells were stained with 1 µg/ml anti-CD47 neutralising antibody (Magrolimab).

Biosimilar Applications

Ligand binding assays
Biologics development
Reference antibody in pipeline drug development
In vivo Animal studies
Reference antibody in ELISA and flow cytometry
Studying of biochemical pathways

Related Products

Biosimilar Technology

The Assay Genie biosimilar antibody range are produced using a revolutionary high throughput technology for monoclonal antibody development. Unlike hybridoma based monoclonal antibodies, this new technology can obtain IgG sequences from immunoreactive B cells directly with no need for hybridoma fusion. With no need for a hybridoma fusion, it will soon be possible to raise monoclonal antibodies from a range of animal species.

Over 1000 immunoreactive B cells can be isolated from a single animal. Such high numbers means greater success in obtaining monoclonal antibodies with higher specificity, sensitivity and affinity. Directly obtaining the IgG sequences also means direct editing and optimisation of antibodies is possible for humanization.

Get a Quote

If you would like a quote, or have a question, get in touch and one of our specialists will be happy to help!

Additional Resources